Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Tucson, AZ
NPI: 1285736033HQ Phone
Get M.D. Daniel's Phone Numberphone_androidMobile
Get M.D. Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardAZ State Medical License
Authors: Alrawashdh, Neda, McBride, Ali, Erstad, Brian, Sweasy, Joann, Persky, Daniel O, Abraham, Ivo
Journal: Value Health
Publication Date: 2022-05-07
Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
Authors: Muhammad Khalid, Irbaz Riaz, Bushra Rahman, Faiz Anwer, Atlantis Russ
Publication Date: 2018-04
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Authors: Andrew Roberts, Ranjana Advani, Brad Kahl, Daniel Persky, John Sweetenham, Dennis Carney, Jianning Yang, Todd Busman, Sari Enschede, Roderick Humerickhouse, John Seymour
Publication Date: 2015-01-19
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Vorinostat, OTHER: Laboratory Biomarker Analysis, DRUG: Cyclophosphamide, DRUG: Prednisone, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, BIOLOGICAL: Pegfilgrastim, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, DRUG: Dacarbazine, DRUG: Brentuximab Vedotin, PROCEDURE: Computed Tomography, BIOLOGICAL: Filgrastim, DRUG: Vinblastine Sulfate, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Venetoclax, DRUG: Ibrutinib, BIOLOGICAL: Obinutuzumab, OTHER: Observation Activity